Metformin has been shown to combat EZH2-high prostate cancer by stimulating SETD2, which regulates EZH2-K735me1 to induce EZH2 destruction, thereby inhibiting prostate cancer metastasis [91]. Here, EZH2 is linked to prostate carcinoma.